Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

BT, Anglo American, GSK and more: What brokers said today

UK wealth managers might be on the cusp of a revival after the beating they’ve taken in the past twelve months, according to analysts at JP Morgan.

Notably, the US bank has upgraded St James's Place PLC (LSE:STJ) to overweight, from neutral, with a similar upgrade for rival Quilter PLC (LSE:QLT).

Read more

BT Group PLC's (LSE:BT.A) short-term issues have been neatly summarised by analysts at US bank JP Morgan ahead of a roadshow by the telco’s still relatively new chief executive Allison Kirkby.

Key takeaways included no plans yet to spin out Openreach with a 2% a year line loss already assumed in BT’s business plans.

Read more

The latest contract win by hVIVO plc has been roundly applauded by brokers.

The clinical research specialist has landed a £2.5 million characterisation study for a Covid variant from an unnamed mid-tier pharma company.

Read more

Anglo American PLC (LSE:AAL) must now deliver its 'bold simplification' of the business in the wake of BHP Ltd's £39bn bid approach for its rival, according to Deutsche Bank.

Anglo claimed its plan is lower-risk and quicker to implement than BHP's.

Read more

Deutsche Bank has maintained its "buy" rating on GSK PLC (LSE:GSK, NYSE:GSK) despite the recent setback in the Zantac litigation as it focused on the long-term potential of the stock.

After hours on Friday, the Delaware Superior Court allowed over 70,000 lawsuits related to the heartburn drug to proceed, creating a significant overhang for the pharmaceutical giant.

Read more

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK